Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Issue 12 (23rd October 2021)

• Record Type: Journal Article
• Authors: An, Jaejin; Niu, Fang; Sim, John J.
• Other Names: Baker William L. guestEditor.; Jackevicius Cynthia A. guestEditor.
• Is Part Of: Pharmacotherapy. Volume 41:Issue 12(2021)
• Page Start: 998
• Page End: 1008
• Publication Date: 2021-10-23
• Subjects: A2 antagonists -- outcomes of care -- proteinuria -- renal disease; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.2633
• Languages: English
• ISSNs: 0277-0008

Abstract

Abstract: Background: Mineralocorticoid receptor antagonist (MRA) when combined with either angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may provide additional benefits of cardiovascular and kidney disease risk reduction in patients with diabetic kidney disease (DKD) and hypertension. We evaluated the effectiveness of combination therapy (MRAs, either spironolactone or eplerenone, plus ACEI/ARB) compared with monotherapy (ACEI/ARB only) in patients with DKD and hypertension. Methods: Retrospective cohort study was performed in patients (age ≥ 18 years) with hypertension, diabetes, and albuminuria between 2008 and 2018 within an integrated health system. MRA with ACEI/ARB compared to ACEI/ARB alone was evaluated on composite of cardiovascular events, progression to end‐stage kidney disease, or all‐cause mortality. Hyperkalemia was compared as a safety outcome. Results: We identified 1282 patients who received MRAs with ACEI/ARBs and 5484 patients who received ACEI/ARBs alone. Median exposure time for combination therapy was 126 days. The rates per 100 person‐years of cardiovascular, kidney, or all‐cause mortality outcomes were 12.2 and 9.2 for combination therapy and monotherapy, respectively (hazard ratios = 1.24, 95% Confidence Interval (CI):0.94, 1.63). Patients receiving combination therapy had greater reduction in urine albumin‐to‐creatinine ratio compared with monotherapy (Mean reduction: 823 and 585 mg/g; p < 0.001, respectively). Hyperkalemia was more frequent in combination therapy versus monotherapy (22.3 vs. 10.9 per 100 person‐years for combination and monotherapy, respectively; hazard ratios = 1.78, 95%CI: 1.42, 2.24). Conclusions: Among patients with DKD and hypertension, the short‐term use of MRAs, either spironolactone or eplerenone, in combination with ACEI/ARBs, was not associated with lower risk of cardiovascular or kidney outcomes compared with ACEI/ARB monotherapy. The risk of hyperkalemia and the short duration of combination therapy may suggest a real‐world clinical challenge for MRA with ACEI/ARB combination therapy.